Atezolizumab

Definition

Atezolizumab is a monoclonal antibody used as an immune checkpoint inhibitor in cancer therapy. It targets and inhibits PD-L1, enhancing the body's immune response against tumors.

5 Must Know Facts For Your Next Test

1. Atezolizumab is approved for use in several types of cancers including non-small cell lung cancer (NSCLC) and urothelial carcinoma.
2. The drug works by blocking the interaction between PD-L1 and its receptors, PD-1 and B7.1, on T-cells.
3. Common side effects include fatigue, nausea, and decreased appetite; more serious adverse effects can include immune-mediated conditions such as pneumonitis or hepatitis.
4. It is administered intravenously, typically over a period of 30 to 60 minutes every three weeks.
5. Patients receiving atezolizumab should be monitored for signs of immune-related adverse reactions and managed accordingly.

Review Questions

• What mechanism does atezolizumab use to enhance the body's immune response against tumors?
• Name two types of cancer for which atezolizumab has been approved as a treatment option.
• What are some common side effects associated with atezolizumab?

Related terms

Pembrolizumab: Another immune checkpoint inhibitor that targets PD-1 instead of PD-L1.

Nivolumab: An immune checkpoint inhibitor similar to pembrolizumab, also targeting PD-1.

Ipilimumab: A monoclonal antibody that targets CTLA-4, another checkpoint protein on T-cells, used in cancer immunotherapy.